Summary & Overview
HCPCS G2216: Take-Home Injectable Naloxone from Opioid Treatment Program
HCPCS Level II code G2216 denotes the take-home supply of injectable naloxone provided by a Medicare-enrolled opioid treatment program. This code is reported in addition to the primary procedure for opioid treatment services to capture the discrete service of dispensing life-saving naloxone for patient use outside the clinic. Nationally, the code matters as a mechanism to document and reimburse programs supplying overdose reversal medication, supporting harm reduction and emergency preparedness across outpatient addiction treatment settings.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will gain a concise briefing on the code's clinical purpose, common billing context, payer coverage landscape, and how it is used alongside primary opioid treatment procedure codes. The publication covers benchmarks and policy-relevant considerations for payers and providers, clarifies service and site definitions, and outlines common modifiers used with the service when available.
This summary is intended for a national audience of policy analysts, billing managers, and clinical program leaders seeking clear, pragmatic information about coding for take-home naloxone distribution in opioid treatment programs.
Billing Code Overview
HCPCS Level II code G2216 represents the take-home supply of injectable naloxone provided by a Medicare-enrolled opioid treatment program. The code is used to report the separate provision of naloxone supplies given to patients to take home, listed in addition to the primary procedure code for the opioid treatment service.
Service type: Take-home medication supply for overdose reversal
Typical site of service: Opioid treatment program / outpatient clinic setting operated by a Medicare-enrolled facility
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient enrolled in a Medicare‑certified opioid treatment program presents for a routine clinic visit after stabilization on medication‑assisted treatment for opioid use disorder. The clinician reviews the patient’s response to therapy, assesses overdose risk factors (history of prior overdose, high opioid tolerance, concurrent benzodiazepine use, recent detoxification, or unstable housing), and determines that take‑home naloxone is clinically appropriate. The program pharmacist or clinician provides counseling on overdose recognition, naloxone administration technique (intranasal or intramuscular depending on the product supplied), storage, and documentation of the take‑home supply. The take‑home naloxone supply is furnished at the clinic and billed in addition to the primary visit or treatment service using G2216 as an adjunct supply code. Typical site of service is an opioid treatment program outpatient clinic or affiliated pharmacy. The typical patient scenario includes adult patients receiving methadone or buprenorphine treatment who are at elevated overdose risk and require a naloxone kit for home or community use.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
23 | Unusual anesthesia | Not typically used with G2216; included for completeness when unexpected anesthesia occurs during a visit unrelated to naloxone supply. |